Navigation Links
VirtualScopics Reports Fourth-Quarter and Full-Year 2012 Results
Date:2/19/2013

44,77528,950,864  Diluted

29,752,26331,873,97729,644,77533,413,824Basic and diluted (loss) earnings per common share

$
( 0.03 )$
.00$
( 0.11 )$
.02* Cost of revenues includes non-cash stock-based compensation expense of $13,188 and $8,749 for the three months ended December 31, 2012 and 2011, respectively and $57,984 and $47,215 for the years ended December 31, 2012 and 2011, respectively. VirtualScopics, Inc. and SubsidiaryConsolidated Balance SheetsDecember 31,20122011Assets(unaudited)Current assetsCash

$
8,523,807$
5,737,009Accounts receivable, net of allowance for doubtful accounts of $15,000 

1,762,5072,435,496Prepaid expenses and other current assets

437,698361,376Total current assets

10,724,0128,533,881Patents, net

1,470,4361,582,938Property and equipment, net

399,569514,230Other assets

5,42827,140Total assets

12,599,44510,658,189Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable and accrued expenses

$
982,035$
843,275Accrued payroll

481,661759,470Unearned revenue

272,509421,486Derivative liabilities

15,950156,596Total current liabilities

1,752,1552,180,827Commitments and ContingenciesStockholders' EquityConvertible preferred stock, $0.001 par value; 15,000,000 sharesauthorized;Series A; 8,400 shares authorized; issued and outstanding, 2,190 at December 31, 2012 and December 31, 2011, respectively, liquidation preference $1,000 per share

22Series B; 6,000 shares authorized; issued and outstanding, 600 at December 31, 2012 and December 31, 2011, liquidation preference $1,000 per share

11Series C-1; 3,000 shares authorized; issued and outstanding, 3,000 and 0 shares at December 31, 2012 and December 31, 2011, respectively; liquidation preference $1,000 per share

3-Series C-2; 3,000 shares authorized; issued and outs
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. VirtualScopics Schedules Second Quarter 2012 Earnings Announcement
2. VirtualScopics Reports 2nd Quarter 2012 Results
3. VirtualScopics Announces Receipt of Notice from Nasdaq
4. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
5. VirtualScopics Receives Issuance of Influential Patent in Canada
6. VirtualScopics Reports 3rd Quarter 2012 Results
7. VirtualScopics Schedules Fourth Quarter and Full Year 2012 Earnings Announcement
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Findings indicate early non-responders unlikely to subsequently,respond, ... benefit,from earlier change in treatment strategy, COLORADO ... data presented at the 2007 International Congress ... be assessed earlier than is presently thought, ...
... Average of More Than Two Hours Per ... 2007 /PRNewswire/ --,Adding the once daily, investigational ... to,Parkinson's patients' existing levodopa (L-dopa) therapy,significantly reduced ... activities for a longer period of time. ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:8/29/2015)... ... 2015 , ... Rio Salado College President Chris Bustamante announced on ... of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the ... and impact through innovative technologies and strategies. , “I am very proud to be ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining ... County Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage ... their outpatient wound center. , Transitioning wound care management providers can be ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... that the Bihar Government would do all that it ... the state //, addressing a HIV/AIDS workshop, organized by ... Control Organization (NACO). ,Expressing concern over the ... the Minster highlighted the need for concerted efforts in ...
... take a deep breath, immediately exhale forcefully and then ... before takeoff. // ,That is the advice ... German initials BVDP), which said the technique relaxes muscles ... ,BVDP chairwoman Christa Roth-Sackenheim advised affected persons to refrain ...
... which are used for calming the nervous, can ... older people. // ,Substances like diphenhydramine, ... create this paradox, says Ursula Sellerberg, spokeswoman for ... in Berlin. ,Diazepam, the main ingredient ...
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... Organization is beginning a five-day nationwide polio immunization campaign in ... children, below the age of five. // ,The ... said, "In fact, we are seeing that the number of ... even feel that in the North of the country which ...
... A research team from Georgia Institute of Technology has ... triposphate (ATP) release and its role in cystic fibrosis. ... micro- and nano-electrodes to the tip of an atomic ... simultaneously monitor topography along with electrochemical activity at the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3
Colloidal Gold Conjugated, Protein A - 12 OD...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: